☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
MAA
Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo
October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma
October 29, 2021
Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo
October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma
October 29, 2021
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma
October 1, 2021
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma
October 1, 2021
Load more...
Back to Home